Related Experiment Video
Updated: Feb 9, 2026

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
Published on: October 9, 2010
Carbonic anhydrase inhibition selectively prevents amyloid β neurovascular mitochondrial toxicity
María E Solesio1, Pablo M Peixoto2, Ludovic Debure3
1Department of Basic Sciences, New York University College of Dentistry, New York, New York.
Abstract:
Mounting evidence suggests that mitochondrial dysfunction plays a causal role in the etiology and progression of Alzheimer's disease (AD). We recently showed that the carbonic anhydrase inhibitor (CAI) methazolamide (MTZ) prevents amyloid β (Aβ)-mediated onset of apoptosis in the mouse brain. In this study, we used MTZ and, for the first time, the analog CAI acetazolamide (ATZ) in neuronal and cerebral vascular cells challenged with Aβ, to clarify their protective effects and mitochondrial molecular mechanism of action. The CAIs selectively inhibited mitochondrial dysfunction pathways induced by Aβ, without affecting metabolic function. ATZ was effective at concentrations 10 times lower than MTZ. Both MTZ and ATZ prevented mitochondrial membrane depolarization and H2 O2 generation, with no effects on intracellular pH or ATP production. Importantly, the drugs did not primarily affect calcium homeostasis. This work suggests a new role for carbonic anhydrases (CAs) in the Aβ-induced mitochondrial toxicity associated with AD and cerebral amyloid angiopathy (CAA), and paves the way to AD clinical trials for CAIs, FDA-approved drugs with a well-known profile of brain delivery.
Insights
Carbonic anhydrase inhibitors (CAIs) like methazolamide and acetazolamide protect brain cells from amyloid-beta toxicity by preserving mitochondrial function. These FDA-approved drugs show promise for Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) clinical trials.
Area of Science:
- Neuroscience
- Mitochondrial Biology
- Pharmacology
Background:
- Mitochondrial dysfunction is increasingly implicated in Alzheimer's disease (AD) pathogenesis.
- Amyloid-beta (Aβ) peptides trigger apoptosis and mitochondrial damage in neuronal and vascular cells.
- Carbonic anhydrase inhibitors (CAIs) have shown potential in preventing Aβ-mediated apoptosis.
Purpose of the Study:
- To investigate the protective effects and mitochondrial mechanisms of CAIs, specifically methazolamide (MTZ) and acetazolamide (ATZ), against Aβ-induced cellular toxicity.
- To elucidate the role of carbonic anhydrases (CAs) in Aβ-induced mitochondrial dysfunction relevant to AD and cerebral amyloid angiopathy (CAA).
Main Methods:
- Neuronal and cerebral vascular cells were challenged with amyloid-beta (Aβ).
- The effects of methazolamide (MTZ) and acetazolamide (ATZ) on mitochondrial function, including membrane potential and hydrogen peroxide generation, were assessed.
- Cellular pH and ATP production were monitored to evaluate metabolic effects.
Main Results:
- CAIs selectively inhibited Aβ-induced mitochondrial dysfunction pathways without impacting overall metabolic function.
- Both MTZ and ATZ prevented mitochondrial membrane depolarization and reactive oxygen species (ROS) generation.
- Acetazolamide (ATZ) demonstrated efficacy at concentrations 10-fold lower than MTZ.
- The drugs did not significantly alter intracellular pH, ATP production, or calcium homeostasis.
Conclusions:
- Carbonic anhydrases play a significant role in Aβ-induced mitochondrial toxicity relevant to AD and CAA.
- CAIs represent a promising therapeutic strategy for AD and CAA, warranting further clinical investigation.
- FDA-approved CAIs offer a potential advantage due to their established safety and brain penetrance.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Feedback Inhibition
Animal Mitochondrial Genetics
The Carbon Cycle
Carbon Skeletons

